SCHEDULE APPOINTMENT: CALL 800.999.1249 OR SCHEDULE ONLINE
Amgen (Rocatinlimab) Asthma Study
If you are interested in participating and believe you meet the requirements, please contact our research staff to learn more at 502.368.0732.
Explore More About These Research Trials
An easy way to track when your study milestones, treatments, or updates are expected.
- Home >
- About >
- Research Institute >
- Current Research Studies >
- Amgen (Rocatinlimab) Asthma Study
AMGEN (ROCATINLIMAB) 18 - 75 YEARS OF AGE {ASTHMA STUDY}
- Rocatinlimab is a monoclonal antibody that targets OX40 and has a dual mechanism of action including blocking OX40-OX40L interaction and reducing the number of OX40 expressing T-cells through ADCC.
- The purpose of the study is to describe the efficacy Rocatinlimab in reducing exacerbations.
- Duration: The maximum study duration for a single subject will be up to 62 weeks, including a screening period of up to 2 weeks, a run-in baseline period of 4 weeks (during which adherence to stable background therapy and daily diary use will be monitored), a 48-week blinded treatment period, and a SFU visit approximately 16 weeks after the last dose of investigational product. All subjects will be dosed every 4 to 8 weeks with either rocatinlimab or placebo to maintain blind.
Key Inclusion Criteria:
- Subjects must be between the ages of 18 and 75 inclusive
- Asthma was diagnosed by a physician for ≥ 12 months prior to the screening visit
- Documented history of ≥ 1 asthma exacerbation in the past year
Key Exclusion Criteria:
- Chronic Obstructive Pulmonary Disease (COPD
- Current smoker, including active vaping of any products and/or marijuana, or former smoker with cessation within 6 months of screening, or history of > 10 pack-years.
Interested in This Research Study?
An easy way to track when your study milestones, treatments, or updates are expected.
Research Study Interest Form
To learn more or express interest in this study, please complete the form below or contact our research team at 502-368-0732.